Klaus Maleck

Dr. Klaus Maleck joined ITM as Chief Financial Officer in June 2021. He has over 25 years of experience as a Biopharmaceutical Industry Executive.

Prior to joining ITM, he served as CEO of TETEC AG, a fully integrated regenerative medicine developer and manufacturer within the Aesculap/B Braun group, which grew under Klaus from 30 employees to one of the largest manufacturers in the field. This followed roles as CFO and CBO at Evotec AG, where he drove key corporate development events, including the Nasdaq listing of the company. Earlier in his career, Klaus was Co-Founder and CFO of BioGeneriX AG, the Biosimilars business of Ratiopharm, and a senior consultant to the life science industry with McKinsey & Co. He began his professional career as a Research Scientist at the Novartis Biotechnology and Genomics Center in NC (USA).

Dr. Klaus Maleck holds an MBA degree, as well as a master's degree in Biotechnology from the ESBS in Strasbourg (France), and a Ph.D. in Biochemistry from the Max Planck Institute in Cologne (Germany).